Intravenous anesthesia in gastroscpoy
Conditions
Interventions
experimental group:Remazolam + Nabrphine 0.15 mg/kg
Male group:Remazolam + Nabrphine 0.15 mg/kg
Female group:Remazolam + Nabrphine 0.15 mg/kg
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with elective gastroscopic surgery, ASA grade I-II; 2. Aged 18-60 years; 3. BMI 18.5-24 kg/m^2; 4. No serious cardiopulmonary diseases; 5. Communication is normal; 6. Voluntary trial and signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Severe respiratory and circulatory system diseases: such as severe coronary heart disease, chronic obstructive pulmonary disease, etc.; 2. Endocrine system diseases: such as pituitary tumor, severe diabetes, hypercortisol syndrome, pheochromocytoma, etc.; 3. Mental and psychological diseases: such as schizophrenia, depression, history of chronic analgesic drug use, history of alcoholism, opioid dependence; 4. Long term drug abuse: including chemotherapy drugs, analgesics, etc.; 5. Complicated with obvious abnormal liver and kidney function; 6. Possible difficult airway; 7. People who are allergic to remiazolam and other narcotic drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median effective dose of remimazolam ;Remimazolam 50% effective dose (ED50) in female patients;Remimazolam ED50 in female patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery time;Repeated dose;Total dose;Ramsay score;Evaluation of analgesic effect during operation (BPS-NI, BPS-NI, Behavioral Pain Scale-Non Intubated);Blood pressure;Heart rate;pulse oxygen saturation;Duration time given initial dose of remimazolam;Ratio of remimazolam to duration of anesthesia;MOAA/S, modified observers assessment alert/sedation; | — |
Countries
China
Contacts
Public ContactTang Lili
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed